{"doi":"10.1097/qad.0b013e328329148e","title":"Clinical experience with the combined use of lopinavir/ritonavir and rifampicin","abstract":null,"journal":"AIDS","year":2009,"id":635791,"datarank":0.5837730447165941,"base_score":3.8918202981106265,"endowment":3.8918202981106265,"self_citation_contribution":0.5837730447165941,"citation_network_contribution":0.0,"self_endowment_contribution":0.5837730447165941,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":48,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1649652,"name":"Hanneke MJ Nijland","orcid":null,"position":1,"is_corresponding":false},{"id":1649654,"name":"Luuk Gras","orcid":null,"position":2,"is_corresponding":false},{"id":1649655,"name":"Rob E Aarnoutse","orcid":null,"position":3,"is_corresponding":false},{"id":259203,"name":"Reinout van Crevel","orcid":"0000-0002-6233-6410","position":4,"is_corresponding":false},{"id":1649656,"name":"Martin Boeree","orcid":null,"position":5,"is_corresponding":false},{"id":488416,"name":"Kees Brinkman","orcid":"0009-0005-4791-1279","position":6,"is_corresponding":false},{"id":172437,"name":"Jan M Prins","orcid":null,"position":7,"is_corresponding":false},{"id":1649659,"name":"Job R Juttmann","orcid":null,"position":8,"is_corresponding":false},{"id":1288142,"name":"David M Burger","orcid":null,"position":9,"is_corresponding":false},{"id":1649651,"name":"Rafaëlla FA L'homme","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Clinical experience with the combined use of lopinavir/ritonavir and rifampicin","abstract":"Thirty-four patients treated concomitantly with lopinavir/ritonavir and rifampicin were evaluated. Overall, only 15% used the recommended increased dose of lopinavir/ritonavir. Of patients on a nonadjusted dose of lopinavir/ritonavir, 67% had a subtherapeutic lopinavir plasma concentration and 38% had a detectable viral load. Forty percent of patients on an increased dose of lopinavir/ritonavir prematurely stopped the drug combination because of adverse events. Combined use of lopinavir/ritonavir and rifampicin is challenging as it implies balancing between suboptimal efficacy and toxicity.","is_dataset_classified":null,"base_score":3.8918202981106265,"endowment":3.8918202981106265,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19352137","pmcid":null,"openalex_id":"https://openalex.org/W2123402665","authors":[],"funders":[],"total_grants":0,"fwci":4.7078,"citation_percentile":0.95397599,"influential_citations":0,"citation_trend":[{"year":2012,"count":10},{"year":2013,"count":5},{"year":2014,"count":3},{"year":2015,"count":4},{"year":2016,"count":3},{"year":2017,"count":4},{"year":2019,"count":2},{"year":2023,"count":1}],"oa_status":"closed","license":"public-domain","oa_locations":[{"url":"http://journals.lww.com/00002030-200904270-00014","host_type":"publisher"},{"url":"https://doi.org/10.1097/qad.0b013e328329148e","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/19352137","host_type":"repository"},{"url":"https://pure.amsterdamumc.nl/en/publications/8a3a4838-b357-45bf-8add-b7c6877b2a86","host_type":"repository"},{"url":"https://pure.amc.nl/en/publications/clinical-experience-with-the-combined-use-of-lopinavirritonavir-and-rifampicin(94368d45-25bd-4661-b4cc-a61bc161853f).html","host_type":"repository"},{"url":"https://hdl.handle.net/2066/79592","host_type":"repository"},{"url":"http://hdl.handle.net/2066/79592","host_type":"repository"}],"fields_of_study":["Pneumocystis jirovecii pneumonia detection and treatment","HIV/AIDS drug development and treatment","Tuberculosis Research and Epidemiology","Adult","Drug Administration Schedule","Drug Therapy, Combination","Female","HIV Infections","HIV Protease Inhibitors","HIV-1","Humans","Lopinavir","Male","Pyrimidinones","Rifampin","Ritonavir","Viral Load"],"mesh_terms":["Adult","Drug Administration Schedule","Drug Therapy, Combination","Female","Humans","Male","Pyrimidinones","Rifampin","HIV-1","HIV Infections","HIV Protease Inhibitors","Ritonavir","Viral Load","Lopinavir"],"keywords":["Lopinavir","Ritonavir","Lopinavir/ritonavir","Rifampicin","Medicine","Pharmacology","Internal medicine","Virology","Viral load","Human immunodeficiency virus (HIV)","Tuberculosis","Pathology","Antiretroviral therapy"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T15:34:21.757749Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}